ReviewNature reviews. Cardiology2017
Antithrombotic therapy for patients with STEMI undergoing primary PCI.
Review in Nature reviews. Cardiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 42 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Precise Antiplatelet THerapy Guided by Platelet Aggregation Function in Ischemic STROKE
Precision Antiplatelet Therapy Guided by Platelet Aggregation Function in Patients With Acute Ischemic STROKE
Who cites it
42 citing papers in PubMed, 2 syntheses or guidelines pooled it, 109 citations in OpenAlex.
- Pooled it
- A meta-analysis and cost-minimization analysis of bivalirudin versus heparin in high-risk patients for percutaneous coronary intervention.Pharmacology research & perspectives · 2021Pooled it
- BMI differences on anticoagulation with bivalirudin vs. heparin during primary PCI: a BRIGHT-4 subanalysis.BMC medicine · 2025Trial
- Impact of opioids on P2Y12 receptor inhibition in patients with ST-elevation myocardial infarction who are pre-treated with crushed ticagrelor: Opioids aNd crushed Ticagrelor In Myocardial infarction Evaluation (ON-TIME 3) trial.European heart journal. Cardiovascular pharmacotherapy · 2022Trial
- Trial
- Inpatient-Onset Versus Outpatient-Onset ST-Segment-Elevation Myocardial Infarction in Patients With Percutaneous Coronary Intervention: A National Registry Study.Journal of the American Heart Association · 2025Article
- Antiplatelet Monotherapies for Long-Term Secondary Prevention Following Percutaneous Coronary Intervention.Journal of clinical medicine · 2025Review
- Serum IL-1β as a Novel Predictor of No-Reflow in STEMI Patients Undergoing Primary PCI.Journal of inflammation research · 2025Article
- Elevated Leukocyte Count and Platelet-Derived Thrombogenicity Measured Using the Total Thrombus-Formation Analysis System in Patients with ST-Segment Elevation Myocardial Infarction.Journal of atherosclerosis and thrombosis · 2024Observational
- Intravenous antiplatelet therapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention : A report from the INVEST-STEMI group.Journal of thrombosis and thrombolysis · 2024Article
- Efficacy and safety of cangrelor as compared to ticagrelor in patients with ST-elevated myocardial infarction (STEMI): a systematic review and meta-analysis.The Egyptian heart journal : (EHJ) : official bulletin of the Egyptian Society of Cardiology · 2024Review
- A novel machine learning-derived four-gene signature predicts STEMI and post-STEMI heart failure.Biomolecules & biomedicine · 2024Article
- Risk of Bleeding Among Cangrelor-Treated Patients Administered Upstream P2YJournal of the Society for Cardiovascular Angiography & Interventions · 2024Article
- Cangrelor - Expanding therapeutic options in patients with acute coronary syndrome.Cardiology journal · 2024Article
- Dual Antiplatelet Therapy with Parenteral P2YJournal of cardiovascular development and disease · 2023Review
- Analgesic drug use in patients with STEMI: Current perspectives and challenges.Frontiers in medicine · 2023Review
- Current and Future Insights for Optimizing Antithrombotic Therapy to Reduce the Burden of Cardiovascular Ischemic Events in Patients with Acute Coronary Syndrome.Journal of clinical medicine · 2022Review
- Current Status and Future Direction of Antithrombotic Therapy for Patients with STEMI Undergoing Primary PCI.Reviews in cardiovascular medicine · 2022Review
- Comprehensive safety profile evaluation of bivalirudin in Chinese ST-segment elevation myocardial infarction patients receiving percutaneous coronary intervention: a prospective, multicenter, intensive monitoring study.BMC cardiovascular disorders · 2022Article
- The effect of heparin administration time on thrombolysis in myocardial infarction flow grade in patients with acute ST-elevation myocardial infarction treated with primary percutaneous coronary intervention.ARYA atherosclerosis · 2022Article
Corrections and comments
- Commented on by
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antithrombotic therapy, including antiplatelet and anticoagulant agents, is the cornerstone of pharmacological treatment to optimize clinical outcomes in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI). Intravenous anticoagulant drugs available for PPCI include the indirect thrombin inhibitors unfractionated heparin and low-molecular-weight heparin, and the direct thrombin inhibitor bivalirudin. Intravenous antiplatelet drugs mainly include glycoprotein IIb/IIIa inhibitors and the P2Y
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.